Healthcare

Cell culturing technology Cellink has bought University of Freiburg's single-cell dispensing spinout Cytena for almost $34m.

Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.

BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

UVC Partners has backed a $13.5m round that came four years after the diagnostic technology spinout of LMU secured a series B featuring UnternehmerTUM.

OUP, Celgene and Astellas Venture Management all supplied a portion of the funding to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

Steady is the assessment that comes to mind, rather than remarkable, when probing the year-on-year direction of corporate venture capital investment in university spinouts.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.